市场调查报告书
商品编码
1397172
全球玻璃体手术器材市场:洞察、竞争格局、市场预测:2028 年Vitrectomy Devices - Market Insights, Competitive Landscape, and Market Forecast - 2028 |
2022 年全球玻璃体手术器械市场规模为 11.2 亿美元,预计在 2023-2028 年预测期内复合年增长率为 7.12%。 玻璃体手术器械的需求主要是由视网膜剥离和糖尿病视网膜病变等视网膜疾病的日益普及所推动的。 此外,眼科领域的技术进步和新产品推出数量的增加是影响市场积极成长的其他主要因素。 此外,预计 2023-2028 年预测期内,与视网膜撕裂和脱离相关的创伤病例数量的增加也将有助于玻璃体切割器械市场的整体成长。
根据IABP下属的2020年视力丧失专家组提供的数据,2020年将有约100万人因糖尿病视网膜病变失明,约300万人出现中度至重度视力丧失。预计他患有残疾。 因此,各种视网膜疾病的日益普及预计将最终推动玻璃体手术器械市场的发展。
此外,国际糖尿病联盟(IDF)2019年提供的数据估计,全球受糖尿病影响的总人数将从2030年的5.78亿增加到2045年的7亿。 因此,糖尿病盛行率的增加也是导致糖尿病视网膜病变病例增加的重要因素,这也将在预测期内推动玻璃体手术器械市场的发展。
玻璃体切割器材市场的另一个主要驱动因素是越来越多地采用先进技术产品和新产品的推出。 例如,2021 年 1 月,D.O.R.C 荷兰眼科研究中心(国际)B.V. 获得加拿大卫生部批准 TissueBlueTM。 本产品用于玻璃体切除手术中内界膜(ILM)的染色。 因此,越来越多的产品上市和批准、眼科领域不断进步的技术进步正在推动玻璃体手术器械市场的成长。
然而,与玻璃体手术相关的併发症和与玻璃体手术器械相关的高成本是可能限制玻璃体切除器械市场成长的一些市场障碍。
本报告研究了全球玻璃体切割器械市场,并提供了市场概述,包括按产品、应用、最终用户、地区和参与市场的公司概况划分的趋势。Masu。
Vitrectomy Devices Market By Product (Vitrectomy Systems And Vitrectomy Accessories), Application (Diabetic Retinopathy, Retinal Detachment, Vitreous Hemorrhage, And Others), End-User (Hospitals, Ophthalmology Clinics, And Ambulatory Surgical Centers), and geography is expected to grow at a steady CAGR forecast till 2028 owing to the increasing prevalence of retinal disorders such as diabetic retinopathy and increase in new product launches and technical advancements in the domain of ophthalmology.
The global Vitrectomy Devices market was valued at USD 1.12 billion in 2022, growing at a CAGR of 7.12% during the forecast period from 2023 to 2028. The demand for Vitrectomy Devices is primarily being boosted by the increasing prevalence of retinal disorders such as retinal detachment, diabetic retinopathy, and others. Additionally, the increase in technological advancements and new product launches in the domain of ophthalmology are other key factors influencing the positive growth of the market. Further, the increasing number of trauma cases associated with retinal tear and detachment is also contributing to the overall growth of the Vitrectomy Devices market during the forecast period from 2023-2028.
According to the data provided by Vision Loss Expert Group 2020, which is a part of IABP estimated that around 1 million people were suffering from blindness due to Diabetic Retinopathy in the year 2020, and around 3 million people had moderate to severe vision impairment, globally. Thus, the rising prevalence of various retinal disorders will eventually boost the market for Vitrectomy Devices.
Additionally, the data provided by the International Diabetes Federation (IDF) 2019, it was estimated that the total number of people suffering from diabetes will increase from 578 million in 2030 to 700 million in 2045, globally. Thus, the increasing prevalence of diabetes is also a significant factor contributing to the rise in the cases of diabetic retinopathy, which will also drive the Vitrectomy devices market during the forecast period.
Another key driver for the Vitrectomy devices market is the increase in the adoption of technological advancements products and new product launches. For Instance, in January 2021, D.O.R.C Dutch Ophthalmic Research Center (International) B.V. received approval of TissueBlueTM, from Health Canada. The product is used for staining of the internal limiting membrane (ILM), during vitrectomy surgeries. Therefore, the rising product launches, approvals, and increase in technological advancements in the domain of ophthalmology are propelling the growth of the vitrectomy devices market.
However, the complications associated with Vitrectomy procedures and the high cost associated with Vitrectomy Devices are some of the market barriers that may restrict the growth of the Vitrectomy Devices market.
Vitrectomy Devices Market by Product (Vitrectomy Systems and Vitrectomy Accessories), Application (Diabetic Retinopathy, Retinal Detachment, Vitreous Hemorrhage, and Others), End-users (Hospitals, Ophthalmology Clinics, and Ambulatory Surgical Centers), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the product segment of the Vitrectomy Devices market, the Vitrectomy Systems category is expected to amass a significant revenue share in the year 2022. This can be attributed to the various advantages provided by the vitrectomy systems such as the presence of smart vitrectomy systems. Smart vitrectomy systems consisting of artificial intelligence, helps in providing real-time assistance to surgeons during the surgery in decision-making and provides more personalized and effective interventions. Additionally, continuous advancements in fluidic control systems and illumination technologies in vitrectomy devices are further contributing to better surgical environments. These systems ensure stable vitrectomy procedures, while improved illumination of the vitrectomy systems facilitates clearer visualization during the surgical procedure. Thus, the advantages provided by the Vitrectomy Systems are some of the key factors contributing to the growth of the segment.
Furthermore, as the demand for this segment grows, various products are launched in the market. For Instance, in March 2022, D.O.R.C Dutch Ophthalmic Research Center (International) B.V launched EVA NEXUS, an integrated system consisting of retina, cataract, and combined surgery capabilities.
Therefore, owing to the above-mentioned advantages and applications provided by Vitrectomy Systems, and the new product launches in this category is expected to register significant growth, thereby driving the growth of the overall Vitrectomy Devices market during the forecast period.
Among all the regions, North America is estimated to account for the largest share of the Vitrectomy Devices market in the year 2022. This can be attributed to the presence of a large patient pool suffering from various ophthalmological disorders. Additionally, easy availability of technologically advanced products, high awareness of diabetic retinopathy, easy availability of skilled ophthalmologists, and presence of major market players are among key factors influencing the growth of the market in North America.
According to a study published in JAMA Ophthalmology in the year 2021, "Prevalence of Diabetic Retinopathy in the US", it was estimated that 9.6 million people in the United States suffered from diabetic retinopathy in 2021. According to the same source, around 1.84 million people in the United States have vision threatening diabetic retinopathy (VTDR). Thus, the rising prevalence of various ophthalmological disorders will boost the market for Vitrectomy Devices in the United States, which in return will boost the overall Vitrectomy devices in North America.
According to the data provided by the Centers for Disease Control and Prevention (CDC) 2023, it was estimated that 29.7 million people, which accounts for 8.9% of the total population in the United States were diagnosed with Diabetes in the year 2021. Thus, the increasing prevalence of diabetes is a significant factor, which is contributing to the rise in the cases of diabetic retinopathy, which will eventually boost the market for Vitrectomy devices in the region.
Further, the presence of key market players and various key product launches and approvals in the region are some of the other factors that are influencing the positive growth of the market in the region. For Example, in April 2022, Carl Zeiss Meditec AG received FDA approval for the QUATERA 700 system.
Therefore, the factors mentioned above, and the presence of key market leaders with increasing product launches and product approvals in the region are some of the important factors which are thereby responsible for driving the overall market for Vitrectomy Devices in North America during the forecast period.
Some of the key market players operating in the Vitrectomy Devices market include: Alcon, Carl Zeiss Meditec AG, Lecia Microsystems, IRIDEX Corporation, Lumines Be Ltd., NIDEK CO., LTD., D.O.R.C Dutch Ophthalmic Research Center (International) B.V., Geuder AG, Optos, Hoya Surgical Optics, BVI, and Johnson & Johnson, Inc.